ClinicalTrials.gg
RecruitingNCT04140344NOTICEUpdated Nov 4, 2026

The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

An interventional study of Text Message Group in Lumbar Spine Degeneration, Lumbar Spine Instability and Lumbar Spondylosis, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Duke University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Spondylosis with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Spondylosis · United States.

Planned enrollment
3rd of 45
224 · median 45
Started
2023
with 4 others
No phase
34 of 63
8 open now
Primary completion
2026-12
later than 6 of 17 live
Registered
37th of 63
by date
Lead sponsor
3 of 63
Duke University

Among the 63 studies in Spondylosis with a site in United States, this one is the 3rd largest by planned enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2023, is one of 34 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 37th registered.

Spondylosis

142 studies on the registry are indexed under Spondylosis; 41 are open to participants now.

Browse Spondylosis studies →

Open to participants now

17 of the 63 studies in Spondylosis with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Spondylosis studies recruiting now, 12 (44%) set no upper age limit and 10 (37%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Spondylosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this single-blind, randomized, controlled study is to assess the efficacy of "informative text messages" vs "traditional handouts" provided to lumbar spine surgery patients post-operatively.

Read the detailed description

A total of 224 adult patients (18 years or older) undergoing spinal fusion surgery at Duke University Hospital, will be recruited from the Duke Department of Neurosurgery and the Duke Department of Orthopedics. Participants will be consented and will complete standard of care outcomes questionnaires (Visual Analogue Scale, Oswestry Disability Index and Euro-Quol 5D) at the pre-operative clinic visit for baseline comparison. Participants will be randomized, through REDCap, with equal probability to either: A) the control group, with standard post-surgery handouts, or B) the experimental group, which will receive text messages for a period of 2 weeks after surgery (daily for the first week, and every other day for the second week). Text messages were designed to be standardized and automated, with an embedded link to a video regarding at-home, post-surgery-care instructions. Patients will be directed not to respond to the text messages, but to call for any questions or concerns. The primary outcome will be a reduction in 30-days post-surgery readmission rates. The secondary outcomes will be a reduction in 30-days post-surgery ED visits rates, back and leg pain scores, and anxiety levels. These outcomes will be assessed via a phone interview at 30-days (up to max of 37 days) post-discharge for both groups.

03

Conditions studied

  • Lumbar Spine Degeneration
  • Lumbar Spine Instability
  • Lumbar Spondylosis

Browse trials for

Keywords

  • Lumbar Fusion
  • Text Message
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary lumbar fusion 1-4 levels
  2. 18 years or older
  3. Degenerative spine diagnosis
  4. Answers YES to all the following screening questions:

    • Do you own a mobile phone that is capable of sending and receiving text messages?
    • Do you know how to text and feel comfortable texting?
    • Are you a regular (at least once a day) text-message user?
    • Are you agreeable to regular contact?

Exclusion criteria

Exclusion Criteria:

  1. Prior lumbar fusions
  2. Tumors/infection/trauma
  3. Prisoners or institutionalized patients
  4. Non-English speaking patients
  5. Patients who smokes or with uncontrolled diabetes
  6. Participants will be removed from study if discharged to a rehabilitation center or discharged beyond 7 days post-operatively (we are expecting \~15% of patients to be discharged to a rehabilitation center or discharged beyond 7 days post-operatively)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    ARM 1: Text Message Group

    The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.

    Other: Text Message Group

  • No intervention
    ARM 2: Control group

    The control group will be given the standard post-op packet that includes detailed instructions on proper wound care and signs and symptoms of infection. They will not receive text messages. The same outcomes will be assessed in both groups through a 30-day post-operative phone call.

Interventions

  • OtherText Message Group

    The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.

    Also known as: Guidance via text messaging to lumbar spine surgery patients post-operatively

06

What researchers measure

Primary outcomes

  1. Change in readmission rates within 30 days post-lumbar spine surgery.

    Change in readmission rates within 30 days post-lumbar spine surgery as measured by questionnaire.

    Time frame: Baseline, 30 days

Secondary outcomes

  1. Change in Emergency Department (ED) visit rates within 30 days post-lumbar spine surgery.

    Change in Emergency Department (ED) visit rates within 30 days post-lumbar spine surgery as measured by questionnaire.

    Time frame: Baseline, 30 days

  2. Change in back and leg pain levels within 30 days post-lumbar spine surgery as measured by "Oswestry Disability Index" (ODI) questionnaire.

    ODI questionnaire is a tool to evaluate a subjective level of functional disability in daily living activities in patients with low back pain. Scores go from 0% (no disability) to 100% (maximum disability possible).

    Time frame: Baseline, 30 days

  3. Change in anxiety/depression levels within 30 days post-lumbar spine surgery as measured by "European Quality of Life-5 Dimension" (EQ-5D) questionnaire.

    The EQ-5D is an instrument to quantify health-related quality of life. Scores can be reported as a five digit number in a range from 11111 (full health) to 55555 (worst health).

    Time frame: Baseline, 30 days

Other outcomes

  1. Change in patient satisfaction levels within 30 days post-lumbar spine surgery.

    Change in patient satisfaction levels within 30 days post-lumbar spine surgery as measured by questionnaire.

    Time frame: Baseline, 30 days

07

Study locations

1 of 1 sites recruiting
  • Duke Neurosurgery and Duke Orthopedics
    Durham, North Carolina 27710, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 53 non-industry interventional studies with no phase under Spondylosis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 42. This study's planned 39 months is above that.

Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 6 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2019
First posted
Oct 25, 2019
StartActual
Sep 7, 2023
Primary completionEst.
Dec 2026was Oct 2026
CompletionEst.
Dec 2027was Oct 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Dec 2026
Nov 4, 2026
Study completion
Oct 2027→Dec 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Oct 2026→Dec 2026
    Study completion Oct 2027→Dec 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04140344
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Oct 25, 2019
Start date
Sep 7, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Claudia E Pamanes, MPH
Contact
claudia.pamanes@duke.edu
(919) 668-0897
Oren N Gottfried, MD FAANS
principal investigator · Duke Neurosurgery

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion